The upregulation of YTHDF1, CD160, TNFRSF25, CTLA4, TNFRSF14, JAK2, and CD244 and knockdown of TNFSF4, NRP1, CD276, and CD244 could be viable targets in STAD. This evidence concerns the gene CD244 and gastric adenocarcinoma.